* OTONOMY REPORTS RESULTS FROM CLINICAL EVALUATION OF OTO-413 HIGHER DOSES IN PATIENTS WITH HEARING LOSS
* OTONOMY INC- HIGHER DOSE COHORTS FOR OTO-413 DEMONSTRATED NO CLINICALLY MEANINGFUL IMPROVEMENT FOR PATIENTS FROM BASELINE
* OTONOMY INC- INTENDS TO EXPLORE STRATEGIC OPTIONS TO ADVANCE AND REALIZE VALUE FROM ITS PIPELINE INCLUDING BOTH OTO-413 AND OTO-825
Source text for Eikon: Further company coverage:
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.